Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HPHA.F
- Price
- 2.63
- Stock movement up
- +0.03 (1.15%)
- Company name
- Heidelberg Pharma AG
- Exchange
- (F ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 122.57M
- Ent value
- 110.76M
- Price/Sales
- 12.87
- Price/Book
- 2.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 1.02%
- 1 year return
- -11.45%
- 3 year return
- -20.02%
- 5 year return
- -11.77%
- 10 year return
- -5.71%
Last updated: 2025-04-17
DIVIDENDS
HPHA.F does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 12.87 |
| Price to Book | 2.98 |
| EV to Sales | 11.63 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 46.60M |
| EPS (TTM) | -0.28 |
| FCF per share (TTM) | -0.70 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.52M |
| Gross profit (TTM) | 7.88M |
| Operating income (TTM) | -23.28M |
| Net income (TTM) | -13.06M |
| EPS (TTM) | -0.28 |
| EPS (1y forward) | -0.76 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.74% |
| Operating margin (TTM) | -244.48% |
| Profit margin (TTM) | -137.16% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 42.62M |
| Net receivables | 1.34M |
| Total current assets | 58.57M |
| Goodwill | 6.11M |
| Intangible assets | 2.76M |
| Property, plant and equipment | 0.00 |
| Total assets | 71.97M |
| Accounts payable | 4.79M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 9.56M |
| Total liabilities | 30.81M |
| Shareholder's equity | 41.16M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -32.44M |
| Capital expenditures (TTM) | 243.19K |
| Free cash flow (TTM) | -32.69M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -31.73% |
| Return on Assets | -18.15% |
| Return on Invested Capital | -31.73% |
| Cash Return on Invested Capital | -79.41% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.60 |
| Daily high | 2.67 |
| Daily low | 2.60 |
| Daily Volume | 0K |
| All-time high | 66.08 |
| 1y analyst estimate | 10.05 |
| Beta | -0.36 |
| EPS (TTM) | -0.28 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 20 Jun 2025 |
Downside potential
Loading...
Downside potential data
| HPHA.F | S&P500 | |
| Current price drop from All-time high | -96.02% | -12.29% |
| Highest price drop | -97.76% | -56.47% |
| Date of highest drop | 30 Aug 2016 | 9 Mar 2009 |
| Avg drop from high | -84.47% | -11.07% |
| Avg time to new high | 222 days | 12 days |
| Max time to new high | 4597 days | 1805 days |
COMPANY DETAILS
Marketcap
122.57M
Marketcap category
Small-cap
Description
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Employees
98
Investor relations
-
SEC filings
CEO
Country
Germany
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets experience a mixed performance, with the pan-European STOXX Europe 600 Index ending slightly higher amid hopes for increased government spending, investors are keeping a close eye ...
March 26, 2025
Heidelberg Pharma ( ETR:HPHA ) Full Year 2024 Results Key Financial Results Revenue: €12.0m (up 21% from FY 2023). Net...
March 22, 2025
Amidst a backdrop of geopolitical tensions and consumer spending concerns, major U.S. stock indexes have experienced fluctuations, closing lower after an initial rise earlier in the week. In such vola...
February 25, 2025
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
February 10, 2025
As global markets navigate a mixed landscape of rising treasury yields, fluctuating consumer confidence, and varied economic data across regions, investors are seeking opportunities that align with th...
December 30, 2024
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
December 27, 2024
Global markets have recently shown resilience, with U.S. indexes approaching record highs and broad-based gains despite geopolitical tensions and policy uncertainties. In the context of these market d...
November 28, 2024
Heidelberg Pharma ( ETR:HPHA ) Third Quarter 2024 Results Key Financial Results Revenue: €3.56m (up 59% from 3Q 2023...
October 12, 2024
Key Insights Insiders appear to have a vested interest in Heidelberg Pharma's growth, as seen by their sizeable...
September 29, 2024
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
September 2, 2024
Next page